Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yongwei Sun

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5937-634X; OpenAlex author ID A5019453814. Sources: OpenAlex.

Their work

Papers
69 (first author 1, last author 19)
Trials
0
Grants
0
Labs led
1
Collaborators
171
Papers, trials and grants by year

2014: 3 papers · 2015: 6 papers · 2016: 5 papers · 2017: 3 papers · 2018: 3 papers · 2019: 7 papers · 2020: 4 papers · 2021: 8 papers · 2022: 12 papers · 2023: 4 papers · 2024: 10 papers · 2025: 3 papers · 2026: 1 paper

Papers 50 of 69

  1. A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing… Last author DOI 10.1158/1078-0432.ccr-25-3359↗
  2. Analysis of hepatitis B virus integration identifies KMT2B as a novel cancer-related gene in pancreatic cancer. Co-author DOI 10.1002/ctm2.70424↗
  3. Serum microRNA-24-based nomogram predicts prognosis for patients with resected pancreatic cancer. Co-author DOI 10.1038/s41598-024-82369-9↗
  4. TMEM105 modulates disulfidptosis and tumor growth in pancreatic cancer via the β-catenin-c-MYC-GLUT1 axis. Co-author DOI 10.7150/ijbs.104598↗
  5. SIN3B Loss Heats up Cold Tumor Microenvironment to Boost Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1002/advs.202402244↗
  6. Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study. Co-author DOI 10.1007/s10620-024-08338-4↗
  7. Corrigendum to "Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC." [Biochem. Biophys. Res. Commun. 499 (3… Co-author DOI 10.1016/j.bbrc.2023.149426↗
  8. AGFG1 increases cholesterol biosynthesis by disrupting intracellular cholesterol homeostasis to promote PDAC progression. Last author DOI 10.1016/j.canlet.2024.217130↗
  9. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  10. A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114633↗
  11. OCIAD2 promotes pancreatic cancer progression through the AKT signaling pathway. Co-author DOI 10.1016/j.gene.2024.148735↗
  12. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  13. MED12 loss activates endogenous retroelements to sensitise immunotherapy in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-332350↗
  14. The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway. Co-author DOI 10.1186/s12935-024-03440-z↗
  15. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11427-022-2146-5↗
  16. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Co-author DOI 10.1007/s13402-022-00741-1↗
  17. ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2022.04.005↗
  18. Coadaptation fostered by the SLIT2-ROBO1 axis facilitates liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-023-36521-0↗
  19. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Co-author DOI 10.1002/cac2.12238↗
  20. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  21. Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2022.05.047↗
  22. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  23. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.103897↗
  24. Modeling of cancer-related body-wide effects identifies LTB4 as a diagnostic biomarker for pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104050↗
  25. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  26. A low amino acid environment promotes cell macropinocytosis through the YY1-FGD6 axis in Ras-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-02159-9↗
  27. HOXA10 promote pancreatic cancer progression via directly activating canonical NF-κB signaling pathway. Last author DOI 10.1093/carcin/bgac042↗
  28. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  29. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil. Co-author DOI 10.3389/fimmu.2022.983116↗
  30. Exploitation and Verification of a Stroma- and Metastasis-Associated Risk Prognostic Signature in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/ph15111336↗
  31. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. Co-author DOI 10.1002/1878-0261.12970↗
  32. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2021.03.016↗
  33. The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation. Co-author DOI 10.1016/j.ebiom.2020.103195↗
  34. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Co-author DOI 10.1038/s41421-021-00271-4↗
  35. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-020-20447-y↗
  36. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Last author DOI 10.1186/s13059-020-02222-w↗
  37. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Co-author DOI 10.7150/ijbs.49243↗
  38. The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer. Co-author DOI 10.7150/thno.51712↗
  39. Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2. Co-author DOI 10.1096/fj.201901237r↗
  40. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/0008-5472.can-19-2689↗
  41. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11866↗
  42. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer. Co-author DOI 10.7150/thno.45124↗
  43. CD90 highly expressed population harbors a stemness signature and creates an immunosuppressive niche in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.051↗
  44. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Co-author DOI 10.1038/s41388-019-0701-1↗
  45. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Last author DOI 10.1038/s41419-019-2072-5↗
  46. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GAB… Co-author DOI 10.1136/gutjnl-2018-317479↗
  47. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1155/2019/8656282↗
  48. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis. Co-author DOI 10.1158/1078-0432.ccr-18-2297↗
  49. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. Co-author PMID 30906634↗
  50. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC. Co-author DOI 10.1016/j.bbrc.2018.03.194↗

Closest collaborators

The 25 strongest of 171 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minwei Yang · 35 shared papers, 2015–2026 · strength 4.16
  2. Yan‐Miao Huo · 35 shared papers, 2014–2026 · strength 3.75
  3. Jian‐Yu Yang · 29 shared papers, 2014–2026 · strength 2.69
  4. Shu‐Heng Jiang · 23 shared papers, 2015–2024 · strength 2.61
  5. Dejun Liu · 25 shared papers, 2014–2024 · strength 2.54
  6. Rong Hua · 29 shared papers, 2014–2024 · strength 2.46
  7. Zhigang Zhang · 23 shared papers, 2015–2024 · strength 2.31
  8. Hong‐Fei Yao · 12 shared papers, 2022–2025 · strength 2.02
  9. Li-Peng Hu · 16 shared papers, 2017–2024 · strength 1.96
  10. Xueliang Fu · 21 shared papers, 2015–2024 · strength 1.83
  11. Zong‐Hao Duan · 9 shared papers, 2022–2026 · strength 1.71
  12. Jia-Hao Zheng · 10 shared papers, 2022–2024 · strength 1.69
  13. Qin-Yuan Jia · 8 shared papers, 2022–2025 · strength 1.45
  14. Jing Xue · 11 shared papers, 2018–2024 · strength 1.35
  15. Junfeng Zhang · 12 shared papers, 2016–2026 · strength 1.28
  16. Yu-Heng Zhu · 6 shared papers, 2022–2025 · strength 1.10
  17. Qing Li · 9 shared papers, 2018–2024 · strength 1.08
  18. Junfeng Zhang · 11 shared papers, 2014–2024 · strength 0.97
  19. Dejun Liu · 8 shared papers, 2016–2025 · strength 0.93
  20. Ningning Niu · 7 shared papers, 2019–2024 · strength 0.90
  21. Ruizhe He · 8 shared papers, 2019–2023 · strength 0.89
  22. Ping Lu · 8 shared papers, 2018–2024 · strength 0.88
  23. Gary Guishan Xiao · 6 shared papers, 2019–2025 · strength 0.79
  24. Qin Yang · 7 shared papers, 2019–2023 · strength 0.76
  25. Yifan Yin · 4 shared papers, 2024 · strength 0.73

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.